(UroToday.com) The 2021 American Urological Association (AUA) Summer School session on Upper Tract Urothelial Carcinoma included a case-based discussion led by moderator Dr. Surena Matin who was joined by panelists Dr. Sima Porten and Dr. Vitaly Margulis. This case highlighted the treatment of Jelmyto (mitomycin) treatment for upper tract urothelial carcinoma. This patient was a 56-year-old with gross hematuria and found to have a congenital solitary functioning right kidney with a circumcaval ureter. She was found to have a 3 cm low-grade Ta lesion in the renal pelvis and underwent two ureteroscopies followed by a percutaneous resection with mitomycin induction to the upper tract via a nephrostomy tube. She was subsequently found to have multiple papillary recurrences throughout the renal pelvis at her 3-month follow-up and FDA compassionate use approval was obtained for Mitogel.